Imaging Outcomes of a Dopaminergic Neuronal Cell Therapy for Parkinson’s Disease: 18-month Results from a Phase 1 Study of Bemdaneprocel (S30.005)
Claire Henchcliffe(University of California, Irvine), David Eidelberg(Northwell Health), N Abid, Kenny Yu(Memorial Sloan Kettering Cancer Center), Suneil K. Kalia(University Health Network), Harini Sarva(Cornell University), Alfonso Fasano(University of Toronto), Ahmed Enayetallah, Nicki Jennings, Andrés M. Lozano(University of Toronto), Antoine Lampron, Viviane Tabar(Memorial Sloan Kettering Cancer Center), Cameron Brennan(Memorial Sloan Kettering Cancer Center), Yilong Ma(Feinstein Institute for Medical Research), Whitney stemple, Marcus Yountz
Cited by 0
Related Papers
The Somatic Genomic Landscape of Glioblastoma
|Cell|2013|5.2k
Tumor mutational load predicts survival after immunotherapy across multiple cancer types
|Nature Genetics|2019|4.4k
Deep Brain Stimulation for Treatment-Resistant Depression
|Neuron|2005|4.1k
Molecular characterization of the tumor microenvironment in breast cancer
|Cancer Cell|2004|1.3k
Subcallosal Cingulate Gyrus Deep Brain Stimulation for Treatment-Resistant Depression
|Biological Psychiatry|2008|1k